Skip to main content
Daniel Judge, MD, Cardiology, Charleston, SC

DanielJudgeMD

Cardiology Charleston, SC

Heart Failure & Transplantation

Cardiology Fellowship Director; Director of Cardiovascular Genetics

Dr. Judge is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Judge's full profile

Already have an account?

  • Office

    171 Ashley Ave
    Charleston, SC 29425
    Phone+1 843-792-1414

Summary

  • I am a board-certified specialist in Advanced Heart Failure & Transplant Cardiology, also boarded in Cardiovascular Disease. I direct the Cardiovascular Genetics program at Medical University of South Carolina, and I am also the Fellowship Program Director for Cardiovascular Disease at MUSC in Charleston, SC.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Cardiovascular Disease, 1996 - 2000
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1993 - 1996
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 1992

Certifications & Licensure

  • SC State Medical License
    SC State Medical License 2018 - 2025
  • MD State Medical License
    MD State Medical License 1996 - 2018
  • Advanced Heart Failure and Transplant Cardiology
    American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
  • Cardiovascular Disease
    American Board of Internal Medicine Cardiovascular Disease

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions
    BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-Type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific SessionsMarch 24th, 2025
  • FDA Approves Acoramidis, BridgeBio’s New ATTR-CM Drug
    FDA Approves Acoramidis, BridgeBio’s New ATTR-CM DrugNovember 23rd, 2024
  • New ATTR-CM Drug Linked to Positive Long-Term Data as FDA Nears Final Decision
    New ATTR-CM Drug Linked to Positive Long-Term Data as FDA Nears Final DecisionNovember 22nd, 2024
  • Join now to see all